GlassScriptPhysician profile
Luminita Iacob
NPI 1477535433
$2,705.47
in general payments reported to CMS, 2019-2025
27 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $509 · 2023: $834 · 2024: $521 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.95 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $411.59 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $315.51 | 2024-2025 | Veozah |
| Abbvie INC. | $204.89 | 2021-2023 | |
| Exeltis, USA INC. | $188.34 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $180.82 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $166.10 | 2023 | Myfembree |
| Mayne Pharma Commercial LLC | $163.57 | 2022-2025 | |
| Organon LLC | $159.75 | 2022-2024 | Nexplanon |
| Coopersurgical, INC. | $148.76 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Kowa Pharmaceuticals America, INC. | $114.80 | 2022-2023 | Seglentis |
| Hologic Sales and Service, LLC | $85.72 | 2022-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Millicent US INC | $71.62 | 2024 | Intrarosa, Femring |
| Biogen, INC. | $67.47 | 2024-2025 | Zurzuvae |
| Kerecis Limited | $57.87 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Shield Therapeutics INC | $53.65 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $47.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.82 | 2021-2023 | |
| Baxter Healthcare | $42.43 | 2025 | Perclot |
| Therapeuticsmd, INC. | $32.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $24.52 | 2023 | Exparel |
| Pfizer INC. | $24.21 | 2025 | |
| Merck Sharp & Dohme LLC | $23.03 | 2021 | |
| Avion Pharmaceuticals | $18.18 | 2023 | Balcoltra |
| Minerva Surgical, INC | $16.62 | 2024 | |
| Dexcom, INC. | $15.65 | 2023 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $15.01 | 2021 | |
| Agile Therapeutics, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luminita Iacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.